Morgan, Alice http://orcid.org/0000-0001-7413-0519
Hartmanis, Sally
Tsochatzis, Emmanuel http://orcid.org/0000-0001-5069-2461
Newsome, Philip N. http://orcid.org/0000-0001-6085-3652
Ryder, Stephen D. http://orcid.org/0000-0001-9649-4444
Elliott, Rachel
Floros, Lefteris
Hall, Richard
Higgins, Victoria
Stanley, George
Cure, Sandrine
Vasudevan, Sharad
Pezzullo, Lynne http://orcid.org/0000-0001-5509-2641
Funding for this research was provided by:
Intercept Pharmaceuticals
Article History
Received: 20 February 2020
Accepted: 26 November 2020
First Online: 22 March 2021
Compliance with ethical standards
:
: Alice Morgan, Sally Hartmanis, Sharad Vasudevan and Lynne Pezzullo have received funding from Intercept Pharmaceuticals for consulting services. Emmanuel Tsochatzis has served on advisory boards for Intercept Pharmaceuticals, Gilead and Pfizer; served as a speaker for Gilead and Intercept Pharmaceuticals. Philip Newsome has received grant funding from Novo Nordisk and Boehringer Ingelheim; consultancy services (on behalf of the University of Birmingham) for Gilead, Intercept Pharmaceuticals, Pfizer, Novo Nordisk, Poxel Pharmaceuticals and Afimmune. Stephen Ryder has served on an advisory board and as a speaker for Intercept Pharmaceuticals. Lefteris Floros, Rachel Elliot and Richard Hall declare they have no conflicts of interest to disclose. Victoria Higgins is an employee of Adelphi Real World who have received funding from Intercept Pharmaceuticals for access to the Adelphi NASH Disease Specific Programme™ (DSP) data. George Stanley has received consultancy fees from Intercept Pharmaceuticals. Sandrine Cure has received consultancy fees from and is a current employee of Intercept Pharmaceuticals.